Putting the award page together from the records…
Putting the award page together from the records…
Chartwell RX LLC received this contract from Aspr/Orm-Sns, Office of Assistant Secretary for Preparedness and Response: $144.58M obligated so far for drugs and biologicals. It runs to 2027-06-22, or to 2029-06-22 if every option is exercised.
Key facts · data as of Oct 22, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50325F80009, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50325F80009_7505_36F79720D0198_3600
Chartwell RX LLC: all federal awards · Department of Health and Human Services: spending · Aspr/Orm-Sns: what it buys · The follow-on: recompete brief
DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS
Up for re-bid: ends 2027-06-22. Recompete brief →
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
4 actions since 2025-06-18. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-15 | P00003 | Option exercised | $45.90M | EXERCISE OPTION ORDERING PERIOD YEAR 3 - DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS |
| 2025-12-12 | P00002 | Supplemental agreement (work within scope) | $0 | MODIFICATION TO UPDATE THE PERIOD OF PERFORMANCE ON ORDERING PERIOD 2. |
| 2025-08-12 | P00001 | Option exercised | $57.67M | EXERCISE OPTIONAL ORDERING PERIOD YEAR 2 DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS |
| 2025-06-18 | 0 | $41.01M | DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗